Home > Research > Publications & Outputs > Hydrogel-forming microneedle arrays made from l...

Electronic data

  • acsmolpharmaceut5b00807

    Rights statement: Copyright of ACS This document is the Accepted Manuscript version of a Published Work that appeared in final form in Molecular Pharmaceutics, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.5b00807

    Accepted author manuscript, 810 KB, PDF-document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

Links

Text available via DOI:

View graph of relations

Hydrogel-forming microneedle arrays made from light-responsive materials for on-demand transdermal drug delivery

Research output: Contribution to journalJournal article

Published
  • John George Hardy
  • Eneko Larraneta
  • Ryan Donnelly
  • Niamh McGoldrick
  • Katarzyna Migalska
  • Maeliosa McCrudden
  • Louise Donnelly
  • Colin McCoy
Close
<mark>Journal publication date</mark>7/03/2016
<mark>Journal</mark>Molecular Pharmaceutics
Issue number3
Volume13
Number of pages8
Pages (from-to)907-914
StatePublished
Early online date21/01/16
Original languageEnglish

Abstract

We describe, for the first time, stimuli-responsive hydrogel-forming microneedle (MN) arrays that enable delivery of a clinically-relevant model drug (ibuprofen) upon application of light. MN arrays were prepared using a polymer prepared from 2-hydroxyethyl methacrylate (HEMA) and ethylene glycol dimethacrylate (EGDMA) by micromolding. The obtained MN arrays showed good mechanical properties. The system was loaded with up to 5% (w/w) ibuprofen included in a light-responsive 3,5-dimethoxybenzoin conjugate. Raman spectroscopy confirmed the presence of the conjugate inside the polymeric MN matrix. In vitro, this system was able to deliver up to three doses of 50 mg of ibuprofen upon application of an optical trigger over a prolonged period of time (up to 160 hours). This makes the system appealing as a controlled release device for prolonged periods of time. We believe that this technology has potential for use in “on-demand” delivery of a wide range of drugs in a variety of applications relevant to enhanced patient care.

Bibliographic note

Copyright of ACS This document is the Accepted Manuscript version of a Published Work that appeared in final form in Molecular Pharmaceutics, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.5b00807